Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3 (IVACFLUS-0203)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03095599 |
|
Recruitment Status :
Completed
First Posted : March 29, 2017
Results First Posted : July 22, 2019
Last Update Posted : July 22, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Influenza, Human | Biological: IVACFLU-S Other: Placebo | Phase 2 Phase 3 |
Seasonal influenza viruses circulate widely and cause disease in humans every year. Seasonal influenza viruses evolve continuously, which means that people can get infected multiple times throughout their lives. Therefore the components of seasonal influenza vaccines are reviewed frequently (currently biannually) and updated periodically to ensure continued effectiveness of the vaccines. The World Health Organization (WHO) recommended that influenza vaccines for use in the 2016-2017 northern hemisphere influenza season contain the following viruses:
- NYMC BX-35 reassortant of B/Brisbane/60/2008 (B)
- NYMC X-179A reassortant of A/California/7/2009 (H1N1)
- NYMC X-263B reassortant of H3/A/Hong Kong/4801/2014 (H3N2)
Among circulating influenza B viruses, there were 2 distinct lineages. The B/Brisbane/60/2008-like viruses were from the influenza B/Victoria lineage and represented the predominant circulating influenza B virus. The preclinical evaluation was conducted with all 3 lots of seasonal vaccine used in the Phase 1 study.The Phase 1 study of the IVACFLU-S that was completed in March 2016 identified no safety concerns and demonstrated the vaccine to be highly immunogenic. Given the promising findings, the current study proposed to expand on the safety data of the vaccine, to confirm the immunological findings, and by including individuals up to age 60 to seek regulatory approval for indication in nonelderly adults based on the Vietnam MOH Guidance on Clinical Trial of Influenza Vaccine serological criteria for assessing seasonal influenza.
Phase 2 was conducted at 1 site (District Health Center of Ben Luc, Long An, Vietnam). Subjects were from two age groups: 18-45 years and 46-60 years. Vaccine safety was determined by the Protocol Safety Review Team (PSRT) and approved by Vietnam Ministry of Health (MOH) before starting Phase 3.
Phase 3 was conducted at 2 sites: District Health Center (DHC) of Ben Luc, Long An, Vietnam; and DHC of Long Thanh, Dong Nai. Subjects were from two age groups: 18-45 years and 46-60 years. Both safety and immunogenicity were assessed.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 889 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Prevention |
| Official Title: | A Phase 2/3 Double Blinded, Randomized, Placebo-Controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S) Produced by IVAC |
| Actual Study Start Date : | March 20, 2017 |
| Actual Primary Completion Date : | October 5, 2017 |
| Actual Study Completion Date : | October 5, 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Vaccine
Received one dose of IVACFLU-S vaccine intramuscularly.
|
Biological: IVACFLU-S
IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains
|
|
Placebo Comparator: Placebo
Received one dose of placebo intramuscularly.
|
Other: Placebo
Phosphate buffered saline with pH 7.2; 0.5 ml/per dose |
- Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE) [ Time Frame: Within 30 minutes of vaccination ]Solicited local AEs were assessed by study staff 30 minutes after vaccination.
- Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE) [ Time Frame: Within 30 minutes of vaccination ]Solicited systemic AEs were assessed by study staff 30 minutes after vaccination.
- Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE), by Severity [ Time Frame: Day 1 to Day 7 ]
Solicited local AEs were assessed by study staff 30 minutes after vaccination then daily for 7 days by the subjects. Subjects were provided a thermometer, ruler and a diary to record the presence or absence of solicited AEs, severity of the solicited AE and use of concomitant medication. AEs were graded as follows:
- Mild: Mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated.
- Moderate: Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated.
- Severe: Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.
- Life-threatening: Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.
- Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE), by Severity [ Time Frame: Day 1 to Day 7 ]
Solicited systemic AEs were assessed by study staff 30 minutes after vaccination then daily for 7 days by the subjects. Subjects were provided a thermometer, ruler and a diary to record the presence or absence of solicited AEs, severity of the solicited AE and use of concomitant medication. AEs were graded as follows:
- Mild: Mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated.
- Moderate: Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated.
- Severe: Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.
- Life-threatening: Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.
- Number and Percentage of Subjects Experiencing Fever [ Time Frame: Day 1 to Day 7 ]Subjects reporting body temperature by maximum severity; Grade 0: <38°C, Grade 1: 38.0 - <38.6°C, Grade 2: 38.6 - <39.3°C, Grade 3: 39.3 - <40.0°C, Grade 4: >= 40.0°C
- Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE) [ Time Frame: Day 1 to Day 21 ]
Unsolicited AEs were observed by study staff while the subject is at a clinic for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a "solicited AE" (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination was to be recorded as an unsolicited AE. The clinician determined whether there was a reasonable possibility that the investigational product(s) caused or contributed to an AE. The following guidelines were used:
- Related: There is a reasonable possibility that the study vaccine caused the AE. "Reasonable possibility" means that there is evidence to suggest a causal relationship between the study product and the AE.
- Not Related: There is not a reasonable possibility that the administration of the study product caused the event.
- Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE) [ Time Frame: Day 1 to Day 91 ]
Unsolicited AEs were observed by study staff while the subject is at a clinic for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a "solicited AE" (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination was to be recorded as an unsolicited AE. The clinician determined whether there was a reasonable possibility that the investigational product(s) caused or contributed to an AE. The following guidelines were used:
- Related: There is a reasonable possibility that the study vaccine caused the AE. "Reasonable possibility" means that there is evidence to suggest a causal relationship between the study product and the AE.
- Not Related: There is not a reasonable possibility that the administration of the study product caused the event.
- Number and Percentage of Subjects With Seroconversion of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens, Overall and by Age Group [ Time Frame: Day 1, Day 22 ]
Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.
Seroconversion is defined as a serum HAI antibody titer meeting the following criteria:
- pre-vaccination titer < 1:10 and a post-vaccination titer measured on Day 22 of ≥ 1:40, or
- pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination measured on Day 22
- Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22, Overall and by Age Group [ Time Frame: Day 1, Day 22 ]Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.
- Geometric Mean Fold Change of Serum Hemagglutination Inhibition (HAI) Antibody Titer, Overall and by Age Group [ Time Frame: Day 1, Day 22 ]Fold change in titer between Day 1 and Day 22. Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.
- Number and Percentage of Subjects With at Least a 4-fold Increase in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer [ Time Frame: Day 22 ]Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.
- Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: All Subjects [ Time Frame: Day 1, Day 22 ]Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H1N1). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.
- Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: Subjects Aged 18-45 [ Time Frame: Day 1, Day 22 ]Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.
- Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: Subjects Aged 46-60 [ Time Frame: Day 1, Day 22 ]Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.
- Geometric Mean Fold Change in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer [ Time Frame: Day 1, Day 22 ]Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
- Aged 18 through 60 years on the day of screening/enrollment.
- Literate (by self-report) and willing to provide written informed consent.
- Able to attend all scheduled visits and to comply with all study procedures.
- Healthy or medically stable, as established by medical history and physical examination. For individuals with medical conditions, symptoms/signs, if present must be stable under controlled or unchanged for the past 3 months. If medication is used to treat the condition, the medication dose must have been stable for at least 1 month preceding vaccination.
For female subjects:
- Not breastfeeding or pregnant (based on negative urine pregnancy test) or plan to become pregnant up to Day 22. Women who are not surgically sterile (hysterectomy or tubal ligation) or post-menopausal for more than 1 year must have negative pregnancy test and, be willing to utilize reliable birth control measures (intrauterine device, hormonal contraception, condom or diaphragm with spermicide) through the Day 22 visit.
Exclusion criteria:
- Current or recent (within 2 weeks of enrollment) acute severe illness with or without fever.
- Participation in another clinical study involving any therapy within the previous 3 months or planned enrollment in such a study during the period of this study.
- Receipt of any non-study vaccine within 4 weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 22 visit.
- Received seasonal influenza vaccine in last 6 months
- Receipt of immune globulin or other blood products within 3 months prior to study enrollment or planned receipt of such products prior to the Day 22 visit.
- Known or suspected congenital or acquired immunodeficiency.
- Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within 6 months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, ≥ 0.5 mg/kg/day; topical steroids are allowed).
- Unstable illness by history or physical examination that in the opinion of the Investigator, might interfere with the conduct or results of the study or pose additional risk to the subject.
- Hypersensitivity after previous administration of any vaccine.
- Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein, and rubber (from the vaccine vial stoppers).
- Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion.
- Known active tuberculosis or symptoms of active tuberculosis, regardless of cause (self-report).
- Current alcohol or drug addiction that in the opinion of the Investigator, might interfere with the ability to comply with study procedures.
- History of Guillain-Barré Syndrome
- Neoplastic disease or any hematologic malignancy.
- Any condition that, in the opinion of the Investigator, would increase the health risk to the subject if he/she participates in the study, or would interfere with the evaluation of the study objectives.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03095599
| Vietnam | |
| Pasteur Institute, Ho Chi Minh City | |
| Ho Chi Minh City, Vietnam | |
| Principal Investigator: | Phan Cong Hung, MD | Pasteur Institute, Ho Chi Minh City |
Documents provided by Institute of Vaccines and Medical Biologicals, Vietnam:
| Responsible Party: | Institute of Vaccines and Medical Biologicals, Vietnam |
| ClinicalTrials.gov Identifier: | NCT03095599 |
| Other Study ID Numbers: |
IVACFLU-S 0203 CVIA 051 ( Other Identifier: PATH ) |
| First Posted: | March 29, 2017 Key Record Dates |
| Results First Posted: | July 22, 2019 |
| Last Update Posted: | July 22, 2019 |
| Last Verified: | May 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Influenza Vaccine |
|
Influenza, Human Respiratory Tract Infections Infections Orthomyxoviridae Infections |
RNA Virus Infections Virus Diseases Respiratory Tract Diseases |